IL-23
42 programs · 42 companies
Programs
42
Companies
42
Active Trials
39
Targeting IL-23
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | Crohn'sNMOSD | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | HCCMeso | |
| DSN-6862 | Daiichi Sankyo | Preclinical | Pancreatic CaNSCLC | |
| Tezecilimab | Regeneron | Approved | DLBCL | |
| Fixalucimab | Innovent Bio | Phase 1/2 | MDD | |
| Gelisertib | Samsung Biologics | Approved | PsoriasisRA | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | GA | |
| CVA-2650 | CureVac | Phase 2 | T2DRB | |
| Ribonesiran | Chugai | Phase 1/2 | MDDGastric Ca | |
| Tezesacituzumab | Jiangsu Hengrui | NDA/BLA | CLLCeliac | |
| CUV-6674 | Clinuvel | Phase 1/2 | MCL | |
| TEM-8322 | Tempus AI | Preclinical | PompeAsthma | |
| Teratinib | Aurinia | Phase 2/3 | Parkinson'sT2D | |
| Adagravorutinib | Boehringer Ingelheim | Phase 3 | IgANET | |
| Zenocagene | Sumitomo Pharma | Approved | Prostate CaHuntington's | |
| SAM-IIT-139 | Samsung Medical Ctr | Phase 3 | Celiac | |
| EOR-IIT-726 | EORTC | Phase 1 | Breast Ca | |
| DUK-IIT-134 | Duke Cancer Institute | Phase 2/3 | MG | |
| MGX-719 | Metagenomi | Preclinical | NASHPTSD | |
| Pexanaritide | Anavex | NDA/BLA | Schizophrenia | |
| SAV-8261 | Cassava Sci | NDA/BLA | SMADLBCL | |
| ARC-5137 | ARCH Venture | Approved | SCD | |
| Zorifotisoran | NexImmune | Preclinical | OCDPNH | |
| Bemacapivasertib | Rigel Pharma | Phase 2 | FLNSCLC | |
| 116-9380 | Jacobio | Phase 2 | RCCPTSD | |
| Mavuinavolisib | RemeGen | Phase 1 | Breast CaCKD | |
| GLO-7885 | Gloria Biosciences | Phase 1 | Huntington's | |
| AJA-7822 | Ajax Ther | Phase 2 | PsAADHD | |
| NVE-9059 | Nvelop Ther | Approved | CLLADHD | |
| Sotozanubrutinib | Recordati | Phase 2/3 | Fabry | |
| PCI-3652 | PCI Biotech | Phase 1 | Ovarian CaSchizophrenia | |
| Riborelsin | ALK-Abello | Phase 3 | Huntington'sBCC | |
| Talainavolisib | Cadila Healthcare | Approved | Atopic Derm | |
| Lisosacituzumab | Lupin Limited | Phase 1 | CSU | |
| Daracilimab | Eurofarma | Preclinical | GA | |
| Daranesiran | Richmond Lab | Preclinical | ALSWet AMD | |
| LAB-8428 | Genomma Lab | Phase 2 | HNSCCAS | |
| RIK-IIT-635 | RIKEN | NDA/BLA | RCC | |
| CAM-IIT-713 | CAMS Peking Union | Phase 1 | Wilms | |
| Mavuzumab | Square Pharma | NDA/BLA | PVPBC | |
| Talalemzoparlimab | Zoetis | Phase 2/3 | Bladder CaGastric Ca | |
| Semazasiran | Veeva Systems | NDA/BLA | MesoAML |